Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-64.01	-63.37	-18.58	-21.48	-26.35	-43.27
Depreciation & Amortization	0.72	0.7	0.61	0.69	0.73	0.87
Stock-Based Compensation	4.71	4.75	5.08	4.64	4.29	3.72
Other Adjustments	40.29	43.11	-1.43	-1.62	3.69	-5.98
Change in Receivables	-0.59	-0.32	0.11	-0.45	50.31	-0.86
Changes in Accounts Payable	0.67	2.27	-1.68	-2.3	-18.7	21.65
Changes in Other Operating Activities	-6.04	-6.07	-7.19	-8.06	-12.91	0.31
Operating Cash Flow	-22.11	-18.92	-23.09	-28.57	1.06	-23.56
Capital Expenditures	-0.48	-0.52	-0.57	-0.67	-0.41	-0.34
Purchases of Investments	-23.17	-14.94	-8.76	-16.4	-53.41	-
Proceeds from Sale of Investments	5.97	2	2.02	63.53	7.67	10.09
Investing Cash Flow	-17.69	-13.46	-7.31	46.45	-46.16	9.75
Issuance of Common Stock	27.71	27.71	27.45	6.51	0.8	38.11
Repurchase of Common Stock	-0.04	-0.02	-0.02	-0.04	-0.02	-0.05
Net Common Stock Issued (Repurchased)	27.67	27.69	27.43	6.48	0.78	38.05
Other Financing Activities	-0.52	-0.74	-0.23	-0.05	0.85	-1.12
Financing Cash Flow	27.47	26.95	35.86	6.42	1.63	36.93
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.46	0.4	-0.1	-0.25	-0.87	-0.02
Net Cash Flow	-11.87	-5.03	10.36	24.06	-44.34	23.09
Free Cash Flow	-22.59	-19.44	-23.66	-29.24	0.65	-23.9
FCF Margin	-152.86%	-133.56%	-249.05%	-326.89%	4.39%	-550.59%
Free Cash Flow Per Share	-0.09	-0.08	-0.12	-0.17	0.00	-0.15
Levered Free Cash Flow	-69.34	-67.15	-27.44	-31.83	-57.57	-20.53
Unlevered Free Cash Flow	-42.84	-37.42	-30.31	-33.16	-54.29	-26.73

Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q